Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.
about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsGenomic assays for Epstein-Barr virus-positive gastric adenocarcinomaEpstein-Barr Virus: Diseases Linked to Infection and TransformationSensitive, microliter PCR with consensus degenerate primers for Epstein Barr virus amplificationBlood disorders typically associated with renal transplantationSoluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeCommutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods.γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation.Standardization of Nucleic Acid Tests for Clinical Measurements of Bacteria and Viruses.Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survivalTargeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELAEpstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetilIdentification of EBV infection in adults with egg specific food allergy.Exacerbated metastatic disease in a mouse mammary tumor model following latent gammaherpesvirus infection.Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profilePosttransplant lymphoproliferative disease after lung transplantation.Atypical Epstein-Barr viral genomic structure in lymphoma tissue and lymphoid cell linesMulticenter Evaluation of Whole-Blood Epstein-Barr Viral Load Standardization Using the WHO International StandardMatched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease.Automated Nucleic Acid Extraction Systems for Detecting Cytomegalovirus and Epstein-Barr Virus Using Real-Time PCR: A Comparison Study Between the QIAsymphony RGQ and QIAcube Systems.Performance of the Real-Q EBV Quantification Kit for Epstein-Barr Virus DNA Quantification in Whole Blood.Asymptomatic Epstein-Barr Virus Shedding in the Urine of Kidney Transplant Recipients: Case Reports and Review of the Literature.Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68.Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.Posttransplant lymphoproliferative disease following liver transplantation.Secondary cancers following allogeneic haematopoietic cell transplantation in adults.T-cell therapy in the treatment of post-transplant lymphoproliferative diseaseManaging post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Determining EBV load: current best practice and future requirements.Epstein-Barr virus serology and PCR: conflicting results in an immunocompetent host. A case report and review of literature.Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review.II. Challenges in the management of post-transplant lymphoproliferative disorder.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Comparison of QIAsymphony automated and QIAamp manual DNA extraction systems for measuring Epstein-Barr virus DNA load in whole blood using real-time PCR.Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.Peripheral Blood Epstein-Barr Viral Nucleic Acid Surveillance as a Marker for Posttransplant Cancer Risk.The Epstein-Barr virus DNA load in the peripheral blood of transplant recipients does not accurately reflect the burden of infected cells.Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cellsGreatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.
P2860
Q24597706-3FAAA38E-FA8B-4992-A42C-108BCA3F8188Q27024034-095F05AD-7F13-41E7-9CFE-CDC2D713B64BQ28074586-E29721A1-8B2C-410F-89F0-CEE0C07B86EEQ30356173-3D566176-6BFF-47A8-86B8-8C3F57F9D380Q33421793-84864FFC-B692-4C17-84B5-C053C791FCA4Q34058118-5D0CA45C-6546-477E-938F-D757EC28A5D0Q34298224-6201E063-B659-4497-B0A5-F562A37856A7Q35068371-943D9AD5-12AB-4260-BA8C-A556BE8B2DECQ35757751-7414FC6D-51A0-4B52-BCEF-D8C197B82128Q36210975-6A009A72-FEAA-4E1C-9878-00A0FC0D1BAAQ36366982-DFE96F1A-4BD2-4078-8704-1621EA872521Q36477951-360C1A30-D527-40DA-BE2E-8681BDB46713Q36552431-00194F6D-DC11-49CA-9421-96FDA5C0CD1AQ36591658-66C07480-D516-46B0-8B1C-336A88EA5B88Q36687528-245E71BE-5F3A-43D3-A141-B6414C47918BQ36701511-012C2E86-6897-430B-8F38-9C52E8ACD22CQ36847178-F3CE08F3-F4B6-4D7A-A3DD-845646CFE45BQ37040476-41B2E6E7-573C-4811-BEEF-914739F24C99Q37145738-C6E758F5-A2D2-43FD-AE2C-783AC34253C6Q37522611-D510D289-7FF4-4C08-9E25-0F10C534BCC9Q37547775-7BEB22DA-CCEF-44BC-9134-B212C53E7789Q37547785-49E850B6-6DE5-49C2-AE72-CAF9930C3AB9Q37579701-6C77A77B-E7F1-401F-8213-3F0DF7AF1A29Q37670926-BFBA5F19-4127-488F-9978-C24DDD150C1BQ37845384-CFA02FAB-5416-4E44-A79F-582EB833B9DCQ37862042-109035D4-5271-462F-8F07-A5B3843BF762Q37880254-E29FF707-E119-464E-963F-7ACFF870BA2BQ38026758-4B668851-5F35-454A-ACF6-CE86D90FD360Q38032320-8288457E-B434-464B-80F2-F7DA07E1175CQ38079834-8BAB4C77-59BF-4744-B1AC-4523A4DA1F6FQ38219320-AA0D489E-7451-440A-BA9E-255FE441BE13Q38311957-7C3E3BF0-C102-4AF6-A09D-FC1110A856D0Q38524036-F49825DC-0392-4690-B97C-24780FA9C1E3Q38563075-93322DDE-DF20-44C7-8DDB-511B11D21553Q38714494-A0865636-B48A-462A-B2C4-3DA61694BCB2Q38833567-39251719-EC3E-41DE-9158-E4950778B2D9Q38908687-ED55A928-B94F-4483-98C3-8C883163508FQ39311630-179E7C5B-97A2-4404-8532-072C842DE863Q39351834-7D792016-0236-45A0-8CDB-68C6D8152187Q39978862-11A94E52-9937-42A7-AC94-1EAFDC27D99C
P2860
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@en
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@nl
type
label
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@en
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@nl
prefLabel
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@en
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@nl
P2860
P356
P1476
Using Epstein-Barr viral load ...... lymphoproliferative disorder.
@en
P2093
Margaret L Gulley
Weihua Tang
P2860
P304
P356
10.1128/CMR.00006-09
P407
P577
2010-04-01T00:00:00Z